

COMPARATIVE STUDY OF EFFECTIVENESS OF LOCAL PLATELET RICH PLASMA VS LOCAL CORTICOSTEROID IN PATIENT WITH “LATERAL EPICONDYLITIS” A RANDOMIZED PROSPECTIVE STUDY

Vineet Sharma¹, Sachin Upadhyay², Hrishikesh¹, Parwez Qureshi³

Received : 05/09/2025
Received in revised form : 22/10/2025
Accepted : 10/11/2025

Keywords:

Lateral epicondylitis, Tennis elbow, Musculoskeletal pain, Platelet Rich Plasma (PRP), Corticosteroid, PRP vs local corticosteroid.

Corresponding Author:

Dr. Hrishikesh,

Email: alcyonas@gmail.com

DOI: 10.47009/jamp.2025.7.6.175

Source of Support: Nil,
Conflict of Interest: None declared

Int J Acad Med Pharm
2025; 7 (6); 940-946



¹Department of Orthopaedics, Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India.

²Professor, Department of Orthopaedics, Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India.

³Assistant Professor, Department of Orthopaedics, Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India.

ABSTRACT

Background: Aim of this study is to compare the clinical efficiency of PRP with that of corticosteroids for treatment of patient with lateral epicondylitis. Lateral epicondylitis is an inflammatory disorder of the lateral epicondyle at the point where the common extensor tendon of the forearm originates. It is the most prevalent persistently painful, incapacitating elbow ailment. Those whose jobs need them to rotate their forearm frequently, such as knitters, carpenters, gardeners, and computer professionals, frequently experience it. There is an equal male to female sex ratio, the age range at which lateral epicondylitis first appears is 35 to 50 years old. Most often, the dominant upper limb is impacted.

Materials and Methods: This randomized prospective study was conducted in N.S.C.B. Medical College & Hospital Jabalpur (M.P.) from August 2022 to February 2024. 47 patients of lateral epicondylitis who fulfilled the inclusion criteria were randomly selected and divided in 2 groups of 23 patients and 24 patients. Group with 24 patients was given corticosteroid injection (triamcinolone acetone) and another group of 23 patients was given PRP injection as treatment modality. Follow up was done at 1, 3 and 6 months after injection. Clinical outcome was assessed using visual analogue scale[VAS], modified mayo performance scale[MAYO], disabilities of the arm, shoulder and hand score[DASH]. Data analysis was performed with help of SPSS (Statistical Package for Social Sciences) for windows. **Result:** DASH score among platelet rich plasma group has declined from pre injection score of 70.17 to 62.46 at 4 weeks, 51.75 at 12 weeks and 33.92 at 24 weeks. VAS score among platelet rich plasma group has declined from the pre injection score of 7.18 to 6.16 at 4 weeks, 4.91 at 12 weeks and 2.88 at 24 weeks. MAYO score among platelet rich plasma group has increased from the pre injection score of 61.04 to 65.42 at 4 weeks, 70 at 12 weeks and 82.29 at 24 weeks. DASH score among steroid group started to decline from the pre injection score of 71.57 to 27.57 at 4 weeks, 38.52 at 12 weeks and 58.69 at 24 weeks. VAS score among steroid group declines from 7.35 of pre injection score to 2.30 at 4 weeks, 3.52 at 12 weeks and 5.69 at 24 weeks. MAYO score among steroid group improves from 60.87 of pre injection score to 83.47 at 4 weeks, 78.91 at 12 weeks and 65 at 24 weeks.

Conclusion: A single injection of autologous platelet rich plasma improves elbow pain and functional activities more effectively than corticosteroid injection in lateral epicondylitis. These improvements were maintained in our follow up period without any significant complications. Corticosteroid gives better results up to 4 weeks and after that improvement was not very significant.

INTRODUCTION

An inflammatory disorder known as lateral epicondylitis develops across the lateral epicondyle at the point where the common extensor tendon of the forearm originates. It is the most prevalent persistently painful, incapacitating elbow ailment. In 1% to 3% of the general population, it results in symptoms. Those whose jobs need them to rotate their forearm frequently, such as knitters, carpenters, gardeners, and computer professionals, frequently experience it. When there is an equal male to female sex ratio, the age range at which lateral epicondylitis first appears is 35 to 50 years old. Most often, the dominant upper limb is impacted.^[1-3]

It's unclear what exactly causes lateral epicondylitis. According to current theory, overuse and aberrant microvascular reactions cause a degenerative process at the common extensor tendon origin of the wrist and fingers.^[4-6] Nirschl noted that the extensor carpi radialis brevis (ECRB) tendon's origin was the site of the fundamental disease. However, the deep surface of the extensor carpi radialis longus (ECRL) and the anteromedial border of the extensor digitorum communis (EDC) may also be involved occasionally. Many treatment modalities, including rest, activity reduction, non-steroidal anti-inflammatory drugs, counterforce braces, massage, physiotherapy, laser treatment, extracorporeal shockwave treatment, acupuncture, ultrasound treatment, and injections of botulinum toxin type A, have been suggested for lateral epicondylitis. Previously Injection of corticosteroids was thought to be the gold standard treatment in lateral epicondylitis. The autologous blood injection and different types of open and arthroscopic operative treatment are also advised for lateral epicondylitis.^[7-11] Currently, platelet rich plasma (PRP) is thought to be the best biological component obtained from autologous blood. It can be injected into various tissues that have activated platelets, releasing large concentrations of cytokines, fibroblast growth factors (FGF), platelet derived growth factors (PDGF), transforming growth factors-beta (TGF- β), and vascular endothelial growth factors (VEGF) at the injection site. These growth factors, which are secreted from platelet-rich plasma, aid in the cellular repair of tendons, bone, and wounds.^[12] Furthermore, the strong antibacterial effectiveness of platelet-rich plasma may help to avoid infections. These specifics prompt us to carry out this investigation.

Aim and Objectives

The aim of this study is to compare the clinical efficiency of PRP with that of corticosteroids for treatment of patient with lateral epicondylitis. Our primary objective is compare the functional outcome following platelet rich plasma and corticosteroid injection in patient with lateral epicondylitis and secondary objective is assess the factors that might play role in recurrence if any and to review the literature.

MATERIALS AND METHODS

This experimental study was conducted at N.S.C.B. Medical College & Hospital, Jabalpur (M.P.) from August 2022 to August 2024. Patients presenting to the OPD of Dept. of Orthopaedics, N.S.C.B. Medical College & Hospital, Jabalpur who were in the age group of 20– 70 years and had symptoms of lateral epicondylitis for more than 3 months not responding to 6 weeks of conservative management were included in this study. Exclusion criteria were Diabetic patients, patients suffering with rheumatoid arthritis, patients with history of trauma or surgery to the lateral epicondyle, patients who have previously received an injection at the lateral epicondyle in the last 3 months and patients suspicious of nerve involvement. 47 patients of lateral epicondylitis who fulfilled the inclusion criteria were randomly selected and divided in 2 groups of 23 patients and 24 patients. Group with 24 patients was given corticosteroid injection (triamcinolone acetonide) and another group of 23 patients was given PRP injection as treatment modality. Follow up was done at 1, 3 and 6 months after injection. Clinical outcome was assessed using visual analogue scale [VAS], modified mayo performance scale [MAYO], disabilities of the arm, shoulder and hand score [DASH]. Data analysis was performed using SPSS (Statistical Package for Social Sciences) for Windows.

RESULTS

47 cases of lateral epicondylitis who met the inclusion criteria were included for the study. There were 32 females with 23 right side lateral epicondylitis and 9 left side lateral epicondylitis. There were 15 males with 12 right side lateral epicondylitis and 3 left side lateral epicondylitis. The mean age was 43.96 years and the range was 30 to 67 years. The mean duration of symptom was 4.9 months.

Table 1: Comparison between vas scores of PRP group and steroid group

MEAN VAS SCORE	PRP GROUP	CORTICOSTEROID GROUP
PRE INJECTION	7.18	7.35
AT 1 MONTH	6.16	2.30
AT 3 MONTH	4.91	3.52
AT 6 MONTH	2.88	5.69


Table 2: Comparison between dash scores of PRP group and steroid group

Mean dash score	PRP group	Corticosteroid group
PRE INJECTION	70.17	71.57
AT 1 MONTH	62.46	27.65
AT 3 MONTH	51.75	38.52
AT 6 MONTH	33.92	58.69



Average DASH score among platelet rich plasma group has declined from pre injection score of 70.17 to 62.46 at 4 weeks, 51.75 at 12 weeks and 33.92 at 24 weeks. Average VAS score among platelet rich plasma group has declined from the pre injection score of 7.18 to 6.16 at 4 weeks, 4.91 at 12 weeks and 2.88 at 24 weeks. Average MAYO score among


platelet rich plasma group has increased from the pre injection score of 61.04 to 65.42 at 4 weeks, 70 at 12 weeks and. 8229 at 24 weeks.

**Table 3: comparison between mayo scores of PRP group and steroid group**


Mean mayo score	PRP group	Corticosteroid group
PRE INJECTION	61.04	60.87
AT 1 MONTH	65.42	83.47
AT 3 MONTH	70	78.91
AT 6 MONTH	82.29	65

Table 4: comparison between vas score, dash score and mayo score in PRP group

P. R. P. GROUP	VAS SCORE	DASH SCORE	MAYO SCORE
PRE-INJECTION	7.167	70.08	61.04
AT 4 WEEKS	6.125	62.46	65.42
AT 12 WEEKS	4.92	51.75	70
AT 24 WEEKS	2.88	33.92	82.29

**Table 5: comparison between vas score, dash score and mayo score in steroid group**

Corticosteroid group	VAS score	Dash score	Mayo score
Pre-injection	7.35	71.57	60.87
At 4 weeks	2.30	27.65	83.47
At 12 weeks	3.52	38.52	78.91
At 24 weeks	5.69	58.70	65



Average DASH score among steroid group started to decline from the pre injection score of 71.57 to 27.57 at 4 weeks ,38.52 at 12 weeks and 58.69 at 24 weeks. Average VAS score among steroid group declines from 7.35 of pre injection score to 2.30 at 4 weeks, 3.52 at 12 weeks and 5.69 at 24 weeks. Average MAYO score among steroid group improves from 60.87 of pre injection score to 83.47 at 4 weeks, 78.91 at 12 weeks and 65 at 24 weeks.

DISCUSSION

This study compared the use of local platelet rich plasma with local corticosteroids for patient with lateral epicondylitis; the use of platelet rich plasma showed to be a safe and simple procedure. Even 6 months after the PRP application, there was still a noticeable difference in the reduction of pain and improvement in functional activity. The effect in the corticosteroid group decreased during further follow up but the result in the PRP group remained stable at the 6 month follow up. A noteworthy finding revealed that the PRP group's DASH scores were higher prior to therapy and improved throughout the first 24 weeks of treatment. Corticosteroid gives better results up to 4 week and after that improvement was not very significant. This strengthens the case for why we concluded that PRP was beneficial.

Lateral epicondylitis is an inflammatory condition at the origin of the extensor tendon of forearm muscles over the lateral epicondyle. It is the commonest chronic disabling painful condition of the elbow. It causes symptoms in 1% to 3% of the general population. It is common in people whose occupation requires frequent rotary motion of the forearm like in carpenter, gardener, computer workers and knitting workers. Some studies have reported female preponderance.^[70,71] However, Shiri R et al., found 1.3% prevalence of lateral epicondylitis without any gender difference.^[72] The findings of our study also support a female preponderance. The age of onset of lateral epicondylitis is between 35 and 50 years with an equal male to female sex ratio. The dominant upper limb is most commonly affected. Chard MD and Hazelman BL stated that lateral epicondylitis involves dominant arm more frequently and occurs equally among all socioeconomic classes.^[73] Similar findings are reflected from the results of our study.

The actual cause of lateral epicondylitis is not clearly understood. Now it is considered that degenerative process occurs at the common extensor tendon origin of the wrist and fingers due to overuse and abnormal micro vascular responses.^[4-6] Nirschl observed that the basic pathology was in the origin of the extensor carpi radialis brevis (ECRB) tendon. But sometimes the anteromedial edge of extensor digitorum communis (EDC) and the deep surface of extensor carpi radialis longus may be involved.

Various modalities of treatment have been recommended for lateral epicondylitis. They are rest, activity modification, non-steroidal anti inflammatory drugs, counterforce braces, massage, physiotherapy, laser treatment, extracorporeal shockwave treatment, acupuncture, ultrasound treatment and botulinum toxin type A injection. Injection of corticosteroids was thought to be the gold standard treatment in lateral epicondylitis previously. The autologous blood injection and different types of open and arthroscopic operative treatment are also advised for lateral epicondylitis.^[7-11] At present,

platelet rich plasma (PRP) is considered as an ideal biological autologous blood derived component. Platelet rich plasma has been utilized and studied since 1970. It can be injected in different tissues where, platelet is activated and it releases high concentrations of transforming growth factor-beta (TGF- β), platelet derived growth factors (PDGF), fibroblast growth factors (FGF), vascular endothelial growth factors (VEGF) and cytokines at the injected site. These growth factors play significant roles in cell proliferation, chemotaxis, cell differentiation and angiogenesis. Bioactive factors like serotonin, histamine, dopamine, calcium and adenosine are also stored in the dense granules in platelets. These non-growth factors plays important role on the biological aspects of wound healing. The platelets in platelet rich plasma are delivered in a clot, which contains several cell adhesion molecules including fibronectin, fibrin and fibronectin. These cell adhesion molecules promote cell migration, and potentiate biological activity of platelet rich plasma. The clot itself promotes wound healing by acting as conductive matrix or scaffold upon which cells can adhere and initiate the wound healing process.^[12] In addition, platelet rich plasma has high antimicrobial potency and this property may prevent infections.

Thus, the goal of this study is to evaluate the therapeutic effectiveness of PRP in comparison to corticosteroids. Leukocyte-enriched PRP was found to be more effective than standard corticosteroid treatment for treating lateral epicondylitis. Mishra and Pavelko,^[68] and Gosens T et al,^[67] observed that both groups significantly improved their pain and function at the short-term follow-up. However, over the long-term follow-up, the pain and functional scores for the PRP group remained high while those for the corticosteroid group returned to baseline. In the first follow-up visits, we saw a stronger response with local corticosteroid injection; however, at six months, the PRP group's recovery was noticeably greater.

There are less number of studies regarding the benefits of platelet rich plasma injection over corticosteroid injection therapy for lateral epicondylitis. The main outcome parameters considered were pain and functional activities of elbow. Currently long term follow up data's regarding the effectiveness of platelet rich plasma are lacking. This study shows six months follow up results using the same outcome parameters.

In the study by Gosen et al,^[67] (March 2011, compared the effectiveness of autologous platelet rich plasma injection to steroid injection therapy in lateral epicondylitis,) it is proved that platelet rich plasma injection is safe and easy. Concerning functional impairment, the corticosteroid group showed better results during the initial period and then declined to base line level. Whereas in platelet rich plasma group symptoms improved progressively.

There was a significant difference in decrease of pain and functional impairment after platelet rich plasma application even after one year.

In this study, DASH score among platelet rich plasma group has declined from pre injection score of 70.17 to 62.46 at 4 weeks, 51.75 at 12 weeks and 33.92 at 24 weeks which is almost similar to the study by Gosen et al,^[67] march 2011, where the pre injection DASH score is 54.3 which declines to 43.1 at 4 weeks, 31.2 at 12 weeks.

In this study the VAS score among platelet rich plasma group has declined from the pre injection score of 7.18 to 6.16 at 4 weeks, 4.91 at 12 weeks and 2.88 at 24 weeks which is almost similar to the study by Gosen et al march 2011, where the pre-injection VAS score of 69.0 declines to 55.7 at 4 weeks, 45.1 at 8 weeks and 40.2 at 12 weeks.

In this study, we have included additional score, MAYO score. MAYO score among platelet rich plasma group has increased from the pre injection score of 61.04 to 65.42 at 4 weeks, 70 at 12 weeks and 8229 at 24 weeks.

In this study the DASH score among steroid group started to decline from the pre injection score of 71.57 to 27.57 at 4 weeks, 38.52 at 12 weeks and 58.69 at 24 weeks, whereas in the study by Gosen et al march 2011, DASH score among steroid group decline similarly up to 12 weeks.

In this study the VAS score among steroid group declines from 7.35 of pre injection score to 2.30 at 4 weeks, 3.52 at 12 weeks and 5.69 at 24 weeks, whereas in the study by Gosen et al march 2011, the decline of VAS score from pre- injection score of 66.2 to 44.3 at 4 weeks and 38.5 at 12 weeks.

In this study the MAYO score among steroid group improves from 60.87 of pre injection score to 83.47 at 4 weeks, 78.91 at 12 weeks and 65 at 24 weeks.

Comparing the results prescribed in this study with the results of six months follow up, the outcome in the corticosteroid group is declined, whereas the outcome in the platelet rich plasma group is maintained. A significant finding is that the platelet rich plasma group had worse pre injection VAS scores and better after 24 weeks. This strengthens our conclusion that the platelet rich plasma injection is better than corticosteroid injection.

In the Mishra and Pavelko,^[68] research, eight weeks after the treatment, the platelet-rich plasma patients noted 60% improvement in their visual analog pain scores versus 16% improvement in control patients (P less than 0.001). Sixty percent (3 of 5) of the control subjects withdrew or sought other treatments after the 8-week period, preventing further direct analysis. Therefore, only the patients treated with platelet-rich plasma were available for continued evaluation. At 6 months, the patients treated with platelet-rich plasma noted 81% improvement in their visual analog pain scores (P = 0.0001). At final follow-up (mean, 25.6 months; range, 12-38 months), the platelet-rich plasma patients reported 93% reduction in pain compared with before the treatment (P = 0.0001).

In our study, patients who received platelet-rich plasma reported a 14.45% (p value= ≤ 0.001), 31.48% (p value= ≤ 0.001) and 59.88% (p value = ≤ 0.001) improvement in their visual analogue pain levels at 4 weeks, 12 weeks and 24 weeks post injection follow up.

In the Hay et al (69) study, Over 2 years, 53 subjects were randomized to injection, 53 to naproxen, and 58 to placebo. Prognostic variables were similar between groups at baseline. At 4 weeks, 48 patients (92%) in the injection group were completely better or improved compared with 30 (57%) in the naproxen group (P < 0.001) and 28 (50%) in the placebo group (P < 0.001). At 12 months, 43 patients (84%) in the injection group had pain scores 0.05. Similarly, In our study, steroid group experienced a 68.5% (p value= ≤ 0.001), 52.07% (p value= ≤ 0.001) and 22.48% (p value= ≤ 0.001) improvement in their visual analogue pain levels at 4 weeks, 12 weeks and 24 weeks post injection follow up.

A recent double-blind randomized control study by Aziza Sayed Omar et al,^[74] has reported that effect of corticosteroid injections lasts for about three months while that of PRP injections last for more than 6 months in providing pain relief in tennis elbow and plantar fasciitis. The work by Aziza Sayed Omar, et al,^[74] is consistent with our findings of a significant improvement in the corticosteroid group at 1 month, and a significantly greater improvement in all outcome measures in the PRP group at the 6-month follow-up.

It is possible that PRP may provide a durable healing effect on the injured tendon. The discrepancy in PRP's effectiveness observed in certain studies could be ascribed to variations in the amount of growth factors supplied to the damaged tendon.

CONCLUSION

In conclusion, the comparative study of treatment of lateral epicondylitis with platelet rich plasma verses corticosteroid injection shows that a single injection of autologous platelet rich plasma improves elbow pain and functional activities more effectively than corticosteroid injection in lateral epicondylitis. These improvements were maintained over in our follow up period without any significant complications.

Corticosteroid gives better results up to 4 week and after that improvement was not very significant. Long term follow up with more number of patients is needed to evaluate lasting benefits of pain relief and functional improvement in lateral epicondylitis.

REFERENCES

1. Nirschl RP, Pettrone FA. Tennis elbow: the surgical treatment of lateral epicondylitis. *J Bone Joint Surg Am.* 1979;61(6):832-839.
2. Jobe FW, Ciccotti MG. Lateral and medial epicondylitis of the elbow. *J Am Acad Orthop Surg.* 1994;2(1):1-8.
3. Hong QN, Durand MJ, Loisel P. Treatment of lateral epicondylitis: where is the evidence? *Joint Bone Spine.* 2004;71(5):369-373.

4. Nirschl RP. Elbow tendinosis/tennis elbow. *Clin Sports Med.* 1992;11(4):851-870.
5. Smith RW, Papadopolous E, Mani R, Cawley MI. Abnormal microvascular responses in a lateral epicondylitis. *Br J Rheumatol.*
6. Wang JH, Iosifidis MI, Fu FH. Biomechanical basis for tendinopathy. *Clin Orthop Relat Res.* 2006;443:320-332.
7. Assendelft WJ, Hay EM, Adshead R, Bouter LM. Corticosteroid injections for lateral epicondylitis: a systematic overview. *Br J Gen Pract.* 1996;46(405):209-216
8. Edwards SG, Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. *J Hand Surg Am.* 2003;28(2):272-278.
9. Smidt N, Assendelft WJ, Arola H, et al. Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. *Ann Med.* 2003;35(1):51-62.
10. Smidt N, van der Windt DA, Assendelft WJ, Deville WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet.* 2002;359(9307):657-662.
11. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2005;143(11):793-797.
12. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Curr Rev Musculoskelet Med.* 2008;1(3-4):165-174.
13. Everts PA, Overdevest EP, Jakimowicz JJ, et al. The use of autologous platelet-leukocyte gels to enhance the healing process in surgery, a review. *Surg Endosc.* 2007;21(11):2063-2068.
14. Major HP. Lawn-tennis elbow [letter]. *Br Med J.* 1983;2:557.
15. Coonrad RW, Hooper WR. Tennis elbow: its courses, natural history, conservative and surgical management. *J Bone Joint Surg.* 1973;55:1177-1182.
16. Ekstrom RA, Holden K. Examination of and intervention for a patient with chronic lateral elbow pain with signs of nerve entrapment. *Phys Ther.* 2002;82(11):1077-1086
17. Walz DM, Newman JS, Konin GP, Ross G. Epicondylitis: Pathogenesis, imaging, and treatment. *Radiographics.* 2010;30(1):167-184
18. Shiri R, Viikari-Juntura E, Varonen H, Heliövaara M. Prevalence and determinants of lateral and medial epicondylitis: A population study. *Am J Epidemiol.* 2006;164(11):1065-1074
19. Calfee RP, Patel A, DaSilva MF, Akelman E. Management of lateral epicondylitis: Current concepts. *J Am Acad Orthop Surg.* 2008;16(1):19-29
20. Levin D, Nazarian LN, Miller TT, et al. Lateral epicondylitis of the elbow: US findings. *Radiology.* 2005;237(1):230-234
21. Mellor S. Treatment of tennis elbow: the evidence. *BMJ.* 2003;327(9):330
22. Thurston AJ. Conservative and surgical treatment of tennis elbow: A study of outcome. *Aust NZ J Surg.* 1998;68(8):568-5728
23. Moore KL, Dalley AF. Clinically oriented anatomy image collection. [Hagerstown, MD]: Lippincott Williams & Wilkins; 2000.- 97
24. Johnson GW, Cadwallader K, Scheffel SB, Epperly TD. Treatment of lateral epicondylitis. *Am Fam Physician.* 200;76:843-848, 849-50;853.
25. Nirschl, R. P.: Patterns of failed tendon healing in tendon injury. In *Sports-Induced Inflammation: Clinical and Basic Science Concepts*, pp. 609-618. Edited by W. B. Leadbetter, J. A. Buckwalter, and S. L. Gordon. Park Ridge, Illinois, American Academy of Orthopaedic Surgeons, 1990.
26. Nirschl, R. P.: Elbow tendinosis/tennis elbow. *Clin. Sports Med.*, 11: 851-870, 1992.
27. Gartner, L. P., and Hiatt, J. L. [editors]: *Connective tissue. In Color Atlas of Histology.* Ed. 2, pp. 42-57. Baltimore, Williams and Wilkins, 1994.
28. Wheeler, P. R.; Burkitt, H. G.; and Daniels, V. G.: Supporting connective tissues. In *Wheeler's Functional Histology: A text and colour Atlas*, edited by H. G. Burkitt, B. Young, and J. W. Heath. Ed. 3, pp. 61-74. New York, Churchill Livingstone, 1993.
29. Rathbun, J. B., and Macnab, I.: The microvascular pattern of the rotator cuff. *J. Bone and Joint Surg.*, 52-B(3): 540-553, 1970.
30. Gelberman, R.; Goldberg, V.; An, K.-N.; and Banes, A.: Tendon. In *Injury and Repair of the Musculoskeletal Soft Tissues: Workshop*, Savannah, Georgia, June 1987, pp. 1-
31. Woo, S. L.-Y., and Tkach, L. V.: The cellular and matrix response of ligaments and tendons to mechanical injury. In *Sports-Induced Inflammation: Clinical and Basic Science Concepts*, pp. 189-202. Edited by W. B. Leadbetter, J. A. Buckwalter, and S. L. Gordon. Park Ridge, Illinois, American Academy of Orthopaedic Surgeons, 1990.
32. Shahabpour M, Kichouh M, Laridon E, Gielen JL, De Mey J. The effectiveness of diagnostic imaging methods for the assessment of soft tissue and articular disorders of the shoulder and elbow. *Eur J Radiol.* 2008;65(2):194-200.
33. Jobe F, Ciccotti MG. Lateral and medial epicondylitis of the elbow. *J Am Acad Orthop Surg.* 1994;2:1-8.
34. Joshi, Sharvari, Santosh Metgud, and C. Ebnezer. "Comparing the effects of manipulation of wrist and ultrasound, friction massage and exercises on lateral epicondylitis: a randomized clinical study." *Indian Journal of Physiotherapy and Occupational Therapy* 7.3 (2013): 205.
35. Lapner, Peter, et al. "Nonoperative treatment of lateral epicondylitis: a systematic review and meta-analysis." *JSES international* 6.2 (2022): 321-330.
36. Wong, Joshua Rui Yen, et al. "The use of platelet-rich plasma therapy in treating tennis elbow: A critical review of randomised control trials." *Journal of Clinical Orthopaedics and Trauma* 32 (2022): 101965.
37. Houck, Darby A., et al. "Treatment of lateral epicondylitis with autologous blood, platelet-rich plasma, or corticosteroid injections: a systematic review of overlapping meta-analyses." *Orthopaedic journal of sports medicine* 7.3 (2019): 2325967119831052.
38. Ozden, Raif, et al. "Management of tennis elbow with topical glyceryl trinitrate." *Acta Orthopaedica et Traumatologica Turcica* 48.2 (2014): 175-180.
39. Lodh, Udeep, Indraneel De, Nego Zion, Siddharth Sekhar Moharana, and Chaitanya Khandelwal. "A prospective observational assessment of the outcome of tennis elbow treatment with platelet rich plasma."
40. Hastie, Graham, Mazen Soufi, James Wilson, and Bibhas Roy. "Platelet rich plasma injections for lateral epicondylitis of the elbow reduce the need for surgical intervention." *Journal of orthopaedics* 15, no. 1 (2018): 239-241.
41. Jindal, Nipun, Yusuf Gaur, Ramesh C. Banshiwal, Ravinder Lamoria, and Vikas 99 Bachhal. "Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study." *Journal of orthopaedic surgery and research* 8 (2013): 1-7.
42. Raeissadat, Seyed Ahmad, Seyed Mansoor Rayegani, Hossein Hassanabadi, Rosa Rahimi, Leyla Sedighpour, and Khalil Rostami. "Is platelet-rich plasma superior to whole blood in the management of chronic tennis elbow: one year randomized clinical trial." *BMC sports science, medicine and rehabilitation* 6 (2014): 1-10.
43. Aben, Aurelie, Lieven De Wilde, Nadine Hollevoet, Carlos Henriquez, Marc Vandeweerdt, Koen Ponnet, and Alexander Van Tongel. "Tennis elbow: associated psychological factors." *Journal of shoulder and elbow surgery* 27, no. 3 (2018): 387-392.
44. Amroodi, Morteza Nakhaei, Ali Mahmuudi, Mostafa Salariyeh, and Arash Amiri. "Surgical treatment of tennis elbow; minimal incision technique." *Archives of Bone and Joint Surgery* 4, no. 4 (2016): 366.
45. Ahmad, Zafar, et al. "The effect of platelet-rich plasma on clinical outcomes in lateral epicondylitis." *Arthroscopy: The Journal of Arthroscopic & Related Surgery* 29.11 (2013): 1851-1862.
46. Ahmad, Zafar, et al. "The effect of platelet-rich plasma on clinical outcomes in lateral epicondylitis." *Arthroscopy: The Journal of Arthroscopic & Related Surgery* 29.11 (2013): 1851-1862.

47. Bateman, Marcus, E. Whitby, S. Kacha, and E. Salt. "Current physiotherapy practice in the management of tennis elbow: a service evaluation." *Musculoskeletal care* 16, no. 2 (2018): 322-326.
48. Branson R, Naidu K, du Toit C, Rotstein AH, Kiss R, McMillan D, Fooks L, Coombes BK, Vicenzino B. Comparison of corticosteroid, autologous blood or 100sclerosant injections for chronic tennis elbow. *Journal of Science and Medicine in Sport* <http://dx.doi.org/10.1016/j.jsams.2016.10.010>
49. Marwaha, Vishal, et al. "Combined steroid and lignocaine injection in resistant cases of tennis elbow: A prospective, interventional study from India." *Journal of family medicine and primary care* 6.3 (2017): 498-501.
50. Bisset, L. —Effect of Corticosteroid Injection, Physiotherapy, or Both on Clinical Outcomes in Patients With Unilateral Lateral Epicondylalgia. *JAMA* (2013): n. Pag. Print.
51. Yilmaz E. Comparison of the efficacy of neural therapy versus steroid injection in the treatment of lateral epicondylitis (tennis elbow). *European Journal of Integrative Medicine*. 2018 Oct 1;23:77-83.
52. Watts, A.C., Morgan, B.W., Birch, A., Nuttall, D. and Trail, I.A., 2020. Comparing leukocyte-rich platelet-rich plasma injection with surgical intervention for the management of refractory tennis elbow. A prospective randomised trial. *Shoulder & Elbow*, 12(1), pp.46-53.
53. Corrado, B., Mazzuocolo, G., Liguori, L., Chirico, V.A., Costanzo, M., Bonini, I., Bove, G. and Curci, L., 2019. Treatment of Lateral Epicondylitis with Collagen Injections: a Pilot Study. *Muscles, Ligaments & Tendons Journal (MLTJ)*, 9(4).
54. Sims SE, Miller K, Elfar JC, Hammert WC. Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. *Hand (N Y)*. 2014 Dec;9(4):419-46. doi: 10.1007/s11552-014-9642-x. PMID: 25414603; PMCID: PMC4235906.
55. Hardy, Richard, Aerika Tori, Hannah Fuchs, Taiyo Larson, Jefferson Brand, and Emily Monroe. "To improve pain and function, platelet-rich plasma injections may be an alternative to surgery for treating lateral epicondylitis: a systematic review." *Arthroscopy: The Journal of Arthroscopic & Related Surgery* 37, no. 11 (2021): 3360-3367.
56. Smidt, Nynke, Willem JJ Assendelft, Daniëlle AWM van der Windt, Elaine M. Hay, Rachelle Buchbinder, and Lex M. Bouter. "Corticosteroid injections for lateral epicondylitis: a systematic review." *Pain* 96, no. 1-2 (2002): 23-40.
57. Altay, T., I. Günel, and H. Öztürk. "Local injection treatment for lateral epicondylitis." *Clinical Orthopaedics and Related Research* (1976-2007) 398 (2002): 127-130.
58. Newcomer, Karen L. MD; Laskowski, Edward R. MD; Idank, David M. DO; McLean, Timothy J. RPT; Egan, Kathleen S. PhM. Corticosteroid Injection in Early Treatment of Lateral Epicondylitis. *Clinical Journal of Sport Medicine* 11(4):p 214-222, October 2001.
59. L. Bisset, N. Smidt, D. A. Van der Windt, L. M. Bouter, G. Jull, P. Brooks, B. Vicenzino, Conservative treatments for tennis elbow—do subgroups of patients respond differently?, *Rheumatology*, Volume 46, Issue 10, October 2007, Pages 1601–1605, <https://doi.org/10.1093/rheumatology/kem192>
60. Price, R., Sinclair, H., Heinrich, I., & Gibson, T. (1991). Local injection treatment of tennis elbow—hydrocortisone, triamcinolone and lignocaine compared. *Rheumatology*, 30(1), 39-44.
61. Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft WJJ. Acupuncture for lateral elbow pain. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD003527. DOI: 10.1002/14651858.CD003527. Accessed 06 June 2024.
62. Runeson, L., and E. Haker. "Iontophoresis with cortisone in the treatment of lateral epicondylalgia (tennis elbow)—a double-blind study." *Scandinavian journal of medicine & science in sports* 12.3 (2002): 136-142.
63. Lo, Marvin Y MD; Safran, Marc R MD. Surgical Treatment of Lateral Epicondylitis: A Systematic Review. *Clinical Orthopaedics and Related Research* 463():p 98-106, October 2007. | DOI: 10.1097/BLO.0b013e3181483dc4
64. Struijs PAA, Smidt N, Arola H, van Dijk CN, Buchbinder R, Assendelft WJJ. Orthotic devices for the treatment of tennis elbow. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD001821. DOI: 10.1002/14651858.CD001821. Accessed 06 June 2024
65. Gosens T, Peerbooms JC, van Laar W, den Ouden BL. Ongoing Positive Effect of Platelet-Rich Plasma Versus Corticosteroid Injection in Lateral Epicondylitis: A Double-Blind Randomized Controlled Trial With 2-year Follow-up. *The American Journal of Sports Medicine*. 2011;39(6):1200-1208. doi:10.1177/0363546510397173
66. Aziza Sayed Omar, Maha Emad Ibrahim, Amal Sayed Ahmed, Mahmoud Said —Local injection of autologous platelet rich plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: Randomized clinical trial, *The Egyptian Rheumatologist*, Volume 34, Issue 1, <https://doi.org/10.1016/j.ejr.2011.12.001>
67. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive Effect of an Autologous Platelet Concentrate in Lateral Epicondylitis in a Double-Blind Randomized Controlled Trial: Platelet-Rich Plasma Versus Corticosteroid Injection with a 1-Year Follow-up. *The American Journal of Sports Medicine*. 2010;38(2):255-262. doi:10.1177/0363546509355445
68. Gosens T, Peerbooms JC, van Laar W, den Ouden BL. Ongoing Positive Effect of Platelet-Rich Plasma Versus Corticosteroid Injection in Lateral Epicondylitis: A Double-Blind Randomized Controlled Trial With 2-year Follow-up. *The American Journal of Sports Medicine*. 2011;39(6):1200-1208. doi:10.1177/0363546510397173
69. Mishra A, Pavelko T. Treatment of Chronic Elbow Tendinosis with Buffered Platelet Rich Plasma. *The American Journal of Sports Medicine*. 2006;34(11):1774-1778. doi:10.1177/0363546506288850
70. Hay EM, Paterson SM, Lewis M, Hosie G, Croft P. Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. *BMJ*. 1999 Oct 9;319(7215):964-8. doi: 10.1136/bmj.319.7215.964. PMID: 10514160; PMCID: PMC28251.
71. Ono Y, Nakamura R, Shimaoka M, Hiruta S, Hattori Y, Ichihara G, Kamijima M, Takeuchi Y. Epicondylitis among cooks in nursery schools. *Occup Environ Med*. 1998 Mar;55(3):172-9. doi: 10.1136/oem.55.3.172. PMID: 9624268; PMCID: PMC1757561.
72. Viikari-Juntura E, Kurppa K, Kuosma E, Huuskonen M, Kuorinka I, Ketola R, Könni U. Prevalence of epicondylitis and elbow pain in the meat-processing industry. *Scand J Work Environ Health*. 1991 Feb;17(1):38-45. doi: 10.5271/sjweh.1736. PMID: 2047805.
73. Shiri R, Viikari-Juntura E, Varonen H, Heliövaara M. Prevalence and determinants of lateral and medial epicondylitis: a population study. *Am J Epidemiol*. 2006 Dec 1;164(11):1065-74. doi: 10.1093/aje/kwj325. Epub 2006 Sep 12. PMID: 16968862
74. Chard MD, Hazleman BL. Tennis elbow—a reappraisal. *Br J Rheumatol*. 1989 Jun;28(3):186-90. doi: 10.1093/rheumatology/28.3.186. PMID: 2659123.
75. Aziza Sayed Omar, Maha Emad Ibrahim, Amal Sayed Ahmed, Mahmoud Said, Local injection of autologous platelet rich plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: Randomized clinical trial, *The Egyptian Rheumatologist*, Volume 34, Issue 2, 2012, Pages 43-49, ISSN 1110-1164, <https://doi.org/10.1016/j.ejr.2011.12.001>.